The trial protocol describes a randomized clinical study enrolling 104 women aged 18–40 years with a diagnosis of postpartum depression occurring within 12 months after delivery. The study team reported that participants will be randomized to either the intervention package—which combines a one-time, single-session psychotherapy with ongoing access to the Motherly app—or a waitlist control that receives the intervention after the post-treatment assessment. Assessments are scheduled across four time points: T1 at baseline (week 1), T2 at mid-treatment (week 2), T3 at post-treatment (week 4), and T4 at follow-up (week 8). The investigators noted the trial will prioritize an intention-to-treat analytic perspective.
Participants allocated to the active arm will receive a single-session psychotherapy. The source did not report the exact therapeutic manual content, session duration, or delivery format beyond that it is a single session; those details appear in the protocol but were not specified in the abstract. After the session, the study team will provide continued, self-guided access to the Motherly app for the remainder of the study period. Waitlist participants will retain standard care and then receive the same intervention after the T3 assessment. The authors framed this package as a potentially scalable, low-cost approach intended to address access barriers—particularly in settings with limited mental health workforce capacity.
The primary outcome will be clinician-rated depressive symptoms measured by the QIDS-C16 at the post-treatment time point (T3, week 4). Secondary outcomes listed by the authors include anxiety, sleep quality, parental stress, and self-reported depression, although the abstract did not enumerate the specific instruments used for each secondary domain beyond the QIDS-C16. The assessment cadence—baseline (T1), mid-treatment (T2), post-treatment (T3), and follow-up (T4)—allows short-term change and early maintenance to be evaluated across an eight-week window.
Investigators indicated that longitudinal analyses will use generalized estimating equations (GEE) to test treatment effects consistent with an intention-to-treat framework. Mediation analyses will be applied to investigate intermediate mechanisms that may explain clinical change, while interaction models will test candidate moderators of treatment effect. The team will run regression analyses to probe associations between process variables (specifically therapeutic alliance and levels of app engagement) and clinical outcomes. The protocol abstract did not specify model covariates, handling of missing data beyond the ITT statement, or targeted effect sizes for powering the trial.
The study received ethical approval from the Ethics Review Board of the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (CAAE: 97532226.8.0000.0068), and written informed consent will be obtained from all participants, the authors reported. Trial registration is provided as ClinicalTrials.gov NCT07925762. The authors declared no competing interests and stated that study data will be available on reasonable request.
The abstract leaves several operational details unspecified. The source did not report the single-session psychotherapy’s theoretical orientation, session length, or whether delivery will be in person or remote. The precise measurement instruments for secondary outcomes were not listed beyond the domains themselves. The plan for handling missing data, the pre-specified covariates for statistical models, and the trial’s power calculations were not reported in the abstract. Those are outstanding protocol items that would need review in the full protocol or supplementary materials to judge risk of bias, generalizability, and the robustness of planned inferences.
Trial registration and ethical approvals are documented in the protocol abstract. The study team framed the combined single-session plus app package as a low-cost strategy aimed at improving scalability and access to treatment for postpartum depression, particularly in low- and middle-income settings, but efficacy and implementation questions remain to be answered by the trial’s completed results.